Growth in Preimplantation Genetic Testing: A Positive Outlook for INVO Fertility

Rising Demand for Preimplantation Genetic Testing Signals Growth for INVO Fertility

The global preimplantation genetic testing (PGT) market is currently experiencing significant expansion, a trend that holds strategic relevance for INVO Fertility amidst the shifting landscape of assisted reproductive technology (ART). Valued at approximately $598.4 million in 2026, the market is projected to reach $1,081.9 million by 2033, reflecting a robust compound annual growth rate of 8.8%. This growth is primarily driven by a concerning rise in infertility rates and growing awareness about hereditary diseases, factors that underscore the increasing need for innovative reproductive solutions such as IVF integrated with PGT. As couples seek to ensure healthier outcomes for their future children, the role of genetic testing in ART becomes crucial.

Currently, kits constitute the dominant product segment within the PGT market, capturing over 55% of market share by 2026. This prevalence owes much to enhancements in standardized workflows combined with greater automation compatibility, making PGT more accessible and efficient. North America leads the global market, supported by a well-developed IVF infrastructure and widespread clinical adoption of these advanced techniques. Meanwhile, the Asia Pacific region is poised for the fastest growth, propelled by an increase in fertility clinics and proactive healthcare policies in countries like China and India. As the average age of first-time mothers continues to climb—from 23 in 1970 to 29 in 2020 in England and Wales—there exists an urgent need for ART solutions, positioning INVO Fertility to capitalize on this trend.

Moreover, advancements in genetic analysis technologies, particularly the integration of next-generation sequencing (NGS) and AI-assisted embryo assessment, enhance PGT practices and clinical outcomes. Such innovations significantly improve pregnancy rates for older mothers, empowering couples to make informed reproductive choices. The growing emphasis on reliable genetic testing under regulatory frameworks like India’s PCPNDT Act further accelerates the adoption of PGT in standard IVF protocols. This not only leads to improved fertility outcomes but also fosters a higher live birth rate, highlighting the critical intersection between technological advancement and patient health. INVO Fertility stands to benefit from these trends as it navigates the evolving market landscape.

In conclusion, as INVO Fertility continues to leverage advancements in genetic and reproductive technologies, its alignment with the upward trends seen in the PGT market bodes well for future growth. The increased focus on AR technologies will likely enhance the company’s offerings, further attracting clients who prioritize both innovation and successful family planning.